Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.

Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.

Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.

Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.

Abstract: The present invention describes the DNA-sequence of the wild type genome as well as all genetic modifications which were introduced into the wild type—and further developed strains, based thereon. Thereby the first genotypic characterization of the developed strains, including the latest production strain, has been accomplished, accounting for the major part of the invention. Furthermore, on the basis of the determined DNA-sequences, potential genes were identified and account, combined with their functional annotation, for another part of the invention. In particular, the gene- and DNA-sequences, as well as protein-sequences derived there out, contribute to the invention which were affected by mutagenic modifications throughout the strain development process, potentially contributing to the increased production yield.

Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AICEs from other species.

Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AICEs from other species.

Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AiCEs from other species.

Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.

Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AiCEs from other species.

Abstract: The present invention describes the DNA-sequence of the wild type genome as well as all genetic modifications which were introduced into the wild type-and further developed strains, based thereon. Thereby the first genotypic characterization of the developed strains, including the latest production strain, has been accomplished, accounting for the major part of the invention. Furthermore, on the basis of the determined DNA-sequences, potential genes were identified and account, combined with their functional annotation, for another part of the invention. In particular, the gene-and DNA-sequences, as well as protein-sequences derived there out, contribute to the invention which were affected by mutagenic modifications throughout the strain development process, potentially contributing to the increased production yield.

Abstract: The present invention relates to the construction and use of expression plasmids in the manufacture of recombinant interleukin-4 (IL-4) and interleukin-4 muteins.

Abstract: The present invention relates to novel hIL-4 mutant proteins, to processes for preparing them, and to their use as medicaments, in particular in overshooting, falsely regulated immune reactions and autoimmune diseases.